Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company’s lead selective Fatty Acid Binding Protein 5 (FABP5) inhibitor that was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium being held in Dijon, France.

Artelo researchers evaluated datasets generated across multiple disease models, tissues, and experimental systems to identify common biological pathways associated with treatment with ART26.12, Artelo's FABP5 inhibitor currently in Phase 1 testing.   Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, announced the results in a presentation titled: Integrative Multi-Omics Across Diverse Indications Identifies Linoleic Acid as a Central Link in FABP5 Inhibition.

The analyses revealed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across indications, suggesting a potential mechanistic link underlying the broad therapeutic activity observed with FABP5 inhibition. This finding is consistent with a recent high-impact research paper published in Science by an independent group from Cornell University which demonstrated the linoleic acid-FABP5 axis was a key driver of cancer growth activity in a model of triple negative breast cancer1.